NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

AnaptysBio, Inc. (ANAB) Stock Analysis

AnaptysBio, Inc. (ANAB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANAB

$47.94

+$2.51 (+5.52%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANAB with… →

ANAB Key Statistics

As of Oct 21, 2026
Trading
Open
$45.48
Previous Close
$45.43
Day's Range
45.48–48.48
52-Week Range
20.18–72.36
Volume
664.42K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.45
Valuation
Market Cap
$1.43B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.46
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.51
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.96
Financials (FY)
Revenue (FY)
$234.60M+157.01%
Net Income (FY)
−$13.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
246.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.90M
1-Year Return
+110.82%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
515.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANAB closed at $47.94, +110.82% over 1 year.

AnaptysBio, Inc. (ANAB) has a market capitalization of $1.43B.

In fiscal 2025, ANAB reported revenue of $234.60M.

ANAB Stock Return by Calendar Year

AnaptysBio, Inc. (ANAB) return since Jan 2017: what $10,000 became

1 year
$10,000 $21,082
+110.82%
5 years
$10,000 $25,205
+152.05%
Since Jan 2017
$10,000 $42,300
+323.00%

If you had invested $10,000 in AnaptysBio, Inc. (ANAB) at the close on January 26, 2017, the earliest close on record here, it would have been worth $42,300 at the close on October 21, 2026: +323.00% in total, +15.97% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+48.33%
2025+266.16%
2024−38.19%
2023−30.88%
2022−10.82%
2021+61.63%
2020+32.31%
2019−74.53%
2018−36.67%
2017+492.47%

As of October 21, 2026.

ANAB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$234.60M−$13.23M−5.6%
2024$91.28M−$145.23M−159.1%
2023$17.16M−$163.62M−953.7%
2022$10.29M−$128.72M−1,251.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$234.60M—$47.90M−$13.23M−5.6%
2024$91.28M—−$114.95M−$145.23M−159.1%
2023$17.16M—−$157.07M−$163.62M−953.7%
2022$10.29M—−$115.15M−$128.72M−1,251.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ANAB Valuation vs Biotechnology Median

Median of 608 stocks
MetricANABBiotechnology medianvs median
P/S ratio13.5113.302% above
Profit margin246.96%−38.31%285.3 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AnaptysBio, Inc. (ANAB) at $1.43B. It is classified in the Biotechnology industry, within the Healthcare sector.

The 52-week range on file runs from $20.18 to $72.36. The most recent close on file for ANAB is $47.94, dated October 21, 2026. That is +$2.51 (+5.52%) against the previous close. The latest close sits 137.56% above that 52-week low.

Financial Health

In fiscal 2025, AnaptysBio, Inc. reported revenue of $234.60M. Against the prior fiscal year total of $91.28M, that is a change of +157.01%. The same year closed with a net loss of $13.23M. The reported profit margin is 246.96%. That is 285.3 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.96.

Across the 4 fiscal years on file, revenue moves from $10.29M in 2022 to $234.60M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 9.46. Measured against sales, the shares trade at 13.51 times revenue. On price-to-sales that is 1.59% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +110.82%. Across 5 years the annualized return works out at +20.31%. Beta against the wider market is reported at 0.45. Annualized volatility over the trailing 9 years is 68.15%.

Growth & Income

No dividend is on file for ANAB.

The strongest complete calendar year on file is 2017 at +492.47%; the weakest is 2019 at −74.53%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is +48.33%.

Peer Comparison

AnaptysBio, Inc. (ANAB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AnaptysBio, Inc. ANAB $1.43B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. AnaptysBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AnaptysBio, Inc.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Visit website →